• Massachusetts: Mass General Brigham has launched a new AI company called AIwithCare to expedite finding patients for clinical trials. The company, which was developed by researchers at Mass General, uses a tool called the RAG-Enabled Clinical Trial Infrastructure for Inclusion Exclusion Review to help find and enroll eligible participants for clinical trials more quickly than standard manual entry procedures. The tool uses generative AI to sort through patient information and health records more quickly. Currently, the company plans to scale use of the tool to other hospitals and health systems. According to Modern Healthcare, Mass General has developed several other AI programs over the last year, including FaceAge, an AI algorithm that predicts a person's biological age and cancer outcomes from a photo. The health system has also partnered with GE HealthCare to further its research into AI applications. (DeSilva, Modern Healthcare, 12/12)
• New York: Last month, New York Gov. Kathy Hochul (D) announced that she plans to sign the Medical Aid in Dying Act, a bill that would allow terminally ill patients to end their lives. The bill applies to adults with incurable, irreversible illnesses who have six months or less to live. Patients will need the sign-off of three doctors, with two doctors testifying to the seriousness of the patient's illness and a psychiatrist or psychologist ensuring that the patient's decision was not made under duress. State senator Brad Hoylman-Sigal (D), who sponsored the bill in the New York Senate, said the law was "not about shortening life," but "about shortening death." So far, 12 U.S. states, as well as the District of Columbia, have passed similar "right-to-die" laws. However, some disability rights activists and religious organizations have spoken out against such laws, with some arguing that they legalize assisted suicide. (Ashford, New York Times, 12/17)
• Utah: Charles Sorenson, president and CEO emeritus of Intermountain Health and founding director of the Intermountain Health Leadership Institute, retired at the end of 2025. According to Becker's Hospital Review, Sorenson spent over 50 years in medicine, including 18 years as a surgeon. Sorenson served as Intermountain's COO from 1998 to 2008 and as its CEO from 2009 to 2016. After retiring as CEO in 2016, he served as CEO emeritus and led the health system's leadership institute as its founding director for the last nine years. "It's been an extraordinary privilege to work alongside remarkable colleagues and friends, people who have consistently put the best interests [of] others first and worked tirelessly to help everyone live the healthiest lives possible," Sorenson said in a post on LinkedIn. After Sorenson's retirement, Carter Dredge became the executive director of all Intermountain's institutes for leadership, healthcare delivery, and mindshare. (Kuchno, Becker's Hospital Review, 12/16)

Generative artificial intelligence offers life science leaders an unprecedented opportunity to revolutionize the drug development process. Explore how life science leaders can leverage generative AI to increase diversity in clinical trials, identify better targets for drug discovery, and reduce drug development timelines — all while promoting equity and improved health outcomes.